Sashi Debnath

Dr. Sashi Debnath

Radiology, The University of Texas Southwestern Medical Center, Dallas, Georgia, USA
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
SDSarasija Das
Sarasija Das
SDSudipto Dey
Sudipto Dey
SPSanujit Patra
Sanujit Patra
ABArindam Bera
Arindam Bera
TGTotan Ghosh
Totan Ghosh
SDSashi Debnath
Sashi Debnath
BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) derivatives have attracted attention as probes in applications like imaging and sensing due to their unique properties like (1) strong absorption and emission in the visible and near-infrared regions of the electromagnetic spectrum, (2) strong fluorescence and (3) supreme photostability. They have also been employed in areas like photodynamic therapy. Over the last decade, BODIPY-based molecules have even emerged as candidates for cancer treatments. Cancer remains a significant health issue world-wide, necessitating a continuing search for novel therapeutic options. BODIPY is a flexible fluorophore with distinct photophysical characteristics and is a fascinating drug development platform. This review provides a comprehensive overview of the most recent breakthroughs in BODIPY-based small molecules for cancer or disease detection and therapy, including their functional potential.

Verified
Journal Article
Open access
PDF file
SDSashi Debnath
Sashi Debnath
NZNing Zhou
Ning Zhou
MMMark McLaughlin
Mark McLaughlin
SRSamuel Rice
Samuel Rice
APAnil K. Pillai
Anil K. Pillai
XSXiankai Sun
Xiankai Sun
In the past two decades, extensive efforts have been made to develop agents targeting prostate-specific membrane antigen (PSMA) for prostate cancer imaging and therapy. To date, represented by two recent approvals of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL by the United States Food and Drug Administration (US-FDA) for positron emission tomography (PET) imaging to identify suspected metastases or recurrence in patients with prostate cancer, PSMA-targeting imaging and theranostic agents derived from small molecule PSMA inhibitors have advanced to clinical practice and trials of prostate cancer. The focus of current development of new PSMA-targeting agents has thus shifted to the improvement of in vivo pharmacokinetics and higher specific binding affinity with the aims to further increase the detection sensitivity and specificity and minimize the toxicity to non-target tissues, particularly the kidneys. The main strategies involve systematic chemical modifications of the linkage between the targeting moiety and imaging/therapy payloads. In addition to a summary of the development history of PSMA-targeting agents, this review provides an overview of current advances and future promise of PSMA-targeted imaging and theranostics with focuses on the structural determinants of the chemical modification towards the next generation of PSMA-targeting agents.

6 December 2022 in Future Pharmacology
Verified
Journal Article
Open access
PDF file
SDSashi Debnath
Sashi Debnath
AAAbhijeet Agarwal
Abhijeet Agarwal
NKNeha Rani Kumar
Neha Rani Kumar
ABAnjan Bedi
Anjan Bedi
Selenium is one of the eight necessary trace elements humans require for active health balance. It contributes in several ways to the proper functioning of selenoprotein. Selenium has received enormous interest recently due to its therapeutic potential against a number of ailments. To date, numerous chemical compounds containing selenium have been investigated for the therapy of cancer and other disorders. Unifying the selenium atom into chemical components (typically organic) greatly increased their bioactivities. We foresee that the structure–property relationship of recently developed materials could significantly decrease the laborious work of background research to achieve target-oriented drug design in coming years. This review summarizes the research progress in the last 10 to 15 years and the application of selenium-containing compounds in the design and synthesis of those materials for potential antioxidant and anticancer agents.

16 June 2015 in The Journal of Physical Chemistry C
Verified
Journal Article
Closed access
SDSashi Debnath
Sashi Debnath
SSSaumya Singh
Saumya Singh
ABAnjan Bedi
Anjan Bedi
KKKothandam Krishnamoorthy
Kothandam Krishnamoorthy
SZSanjio S. Zade
Sanjio S. Zade

11 July 2016 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
SDSashi Debnath
Sashi Debnath
SCSundaresan Chithiravel
Sundaresan Chithiravel
SSSagar Sharma
Sagar Sharma
ABAnjan Bedi
Anjan Bedi
KKKothandam Krishnamoorthy
Kothandam Krishnamoorthy
SZSanjio S. Zade
Sanjio S. Zade

19 May 2017 in Organometallics
Verified
Journal Article
Closed access
SBSushil Ranjan Bhatta
Sushil Ranjan Bhatta
VBVarun Bheemireddy
Varun Bheemireddy
GVGonela Vijaykumar
Gonela Vijaykumar
SDSashi Debnath
Sashi Debnath
ATArunabha Thakur
Arunabha Thakur